{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:31Z","timestamp":1792788451200,"version":"4.5.0"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmunity and autoimmune diseases arise when the immune system erroneously targets self-antigens leading to tissue damage. Consequently, immunomodulatory and mainly immunosuppressive drugs comprise the conventional treatment in conditions such as systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis. However, many of these agents often fall short of providing a cure and have a limit on symptom management. This underscores the urgent need for even more advanced therapies for patients to constrain progressive disability. Therefore, currently, researchers explore the potential of chimeric antigen receptor (CAR) T-cell therapy for autoimmune diseases considering its success in cancer treatment and specifically in hematological malignancies. This review will examine recent advancements in CAR T-cell therapy for autoimmune disorders, highlighting how CAR T cells can be engineered to precisely target and eliminate autoreactive immune cells that drive these debilitating diseases, particularly those affecting the nervous system such as Multiple sclerosis, Myasthenia gravis, Neuromyelitis optica, Stiff-person syndrome, Autoimmune encephalitis, MOG-antibody disease and Chronic inflammatory demyelinating polyneuropathy. Also, through an analysis of preclinical and clinical data, we will assess the efficacy, safety, potential side effects and limitations of these innovative therapies. Lastly, we will underline the transformative potential of CAR T-cells in Autoimmune Neurology, offering a promising new hope for treatment where conventional therapies have failed.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1604174","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T05:24:07Z","timestamp":1752816247000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["CAR T-cells meet autoimmune neurological diseases: a new dawn for therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Nikolaos A.","family":"Chinas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Alexopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/86280","article-title":"Autoimmunity versus horror autotoxicus: the struggle for recognition","volume":"2","author":"Silverstein","year":"2001","journal-title":"Nat Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(02)00675-x","article-title":"The mechanism and regulation of chromosomal V(D)J recombination","author":"Bassing","year":"2002","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.0000000000000128","article-title":"Immunological mechanisms of tolerance: Central, peripheral and the role of T and B cells","volume":"13","author":"Meng","year":"2023","journal-title":"Asia Pac Allergy"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1911109","article-title":"Tolerance in the age of immunotherapy","volume":"383","author":"Bluestone","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1457189","article-title":"Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations","volume":"15","author":"Ge","year":"2024","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e20231314","DOI":"10.1084\/jem.20231314","article-title":"B cell tolerance and autoimmunity: Lessons from repertoires","volume":"221","author":"Deguine","year":"2024","journal-title":"J Exp Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-7-325","article-title":"The Autoimmune Disease Database: a dynamically compiled literature-derived database","volume":"7","author":"Karopka","year":"2006","journal-title":"BMC Bioinf"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.664664","article-title":"Autoimmune disorders of the nervous system: pathophysiology, clinical features, and therapy","volume":"12","author":"Bhagavati","year":"2021","journal-title":"Front Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.autrev.2011.05.012","article-title":"Autoimmune disorders affecting both the central and peripheral nervous system","volume":"11","author":"Kamm","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108361","article-title":"Common innate pathways to autoimmune disease","volume":"212","author":"Langan","year":"2020","journal-title":"Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders","volume":"9","author":"Song","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/ajhp\/zxad247","article-title":"The evolution of multiple sclerosis disease-modifying therapies: An update for pharmacists","volume":"81","author":"Edinger","year":"2024","journal-title":"Am J Health Syst Pharm"},{"key":"B14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/164_2021_550","article-title":"Adverse effects of immunosuppression: infections","volume":"272","author":"Handley","year":"2022","journal-title":"Handb Exp Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/antib12030046","article-title":"Expanding the reach of monoclonal antibodies: A review of synthetic nucleic acid delivery in immunotherapy","volume":"12","author":"Chung","year":"2023","journal-title":"Antibodies (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030663","article-title":"CAR-T: what is next","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3246-4","article-title":"CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory\/relapsed acute lymphoblastic leukemia: results of a case-controlled study","volume":"97","author":"Wei","year":"2018","journal-title":"Ann Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases","volume":"23","author":"Haghikia","year":"2024","journal-title":"Lancet Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000001062","article-title":"Releasing our model T - chimeric antigen receptor (CAR) T-cells for autoimmune indications","volume":"37","author":"Wobma","year":"2025","journal-title":"Curr Opin Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103350","article-title":"Advances in chimeric antigen receptor T cell therapy for autoimmune and autoinflammatory diseases and their complications","volume":"150","author":"Zeng","year":"2025","journal-title":"J Autoimmun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1519671","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity","volume":"15","author":"Kong","year":"2025","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"DhatChinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00371","article-title":"Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells","volume":"4","author":"Chmielewski","year":"2013","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-1109","article-title":"Shaping functional avidity of CAR T cells: affinity, avidity, and antigen density that regulate response","volume":"20","author":"Greenman","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010208","article-title":"Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function","volume":"12","author":"Barden","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","article-title":"Designing chimeric antigen receptors to effectively and safely target tumors","volume":"33","author":"Jensen","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.724211","article-title":"Reducing hinge flexibility of CAR-T cells prolongs survival in vivo with low cytokines release","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051182","article-title":"Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.008","article-title":"Refining chimeric antigen receptors via barcoded protein domain combination pooled screening","volume":"31","author":"Rios","year":"2023","journal-title":"Mol Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.639818","article-title":"The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28","volume":"12","author":"Muller","year":"2021","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR-T cells - new therapeutic opportunities in hematology","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/BS9.0000000000000173","article-title":"CAR-T cell therapy: Where are we now, and where are we heading","volume":"5","author":"Wang","year":"2023","journal-title":"Blood Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cells12111534","article-title":"CAR-based therapy for autoimmune diseases: A novel powerful option","volume":"12","author":"M\u0171zes","year":"2023","journal-title":"Cells"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-024-01034-5","article-title":"Current advancements in cellular immunotherapy for autoimmune disease","volume":"47","author":"Berry","year":"2025","journal-title":"Semin Immunopathol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108409","article-title":"CAR Treg: A new approach in the treatment of autoimmune diseases","volume":"102","author":"Beheshti","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI168601","article-title":"Tregs with an MHC class II peptide-specific chimeric antigen receptor prevent autoimmune diabetes in mice","volume":"133","author":"Spanier","year":"2023","journal-title":"J Clin Invest"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1207108","article-title":"Regulatory T cells targeting a pathogenic MHC class II: Insulin peptide epitope postpone spontaneous autoimmune diabetes","volume":"14","author":"Obarorakpor","year":"2023","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114994","article-title":"Combinatorial genetic engineering strategy for immune protection of stem cell-derived beta cells by chimeric antigen receptor regulatory T cells","volume":"43","author":"Barra","year":"2024","journal-title":"Cell Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00760","article-title":"B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers","volume":"11","author":"van Langelaar","year":"2020","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abo0777","article-title":"Antigen-specific depletion of CD4+ T cells by CAR T cells reveals distinct roles of higher- and lower-affinity TCRs during autoimmunity","volume":"7","author":"Yi","year":"2022","journal-title":"Sci Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200080","article-title":"CAR-T cell-mediated B-cell depletion in central nervous system autoimmunity","volume":"10","author":"Gupta","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab093","article-title":"Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity","volume":"144","author":"Mitsdoerffer","year":"2021","journal-title":"Brain"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3579","article-title":"Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes","volume":"105","author":"Mekala","year":"2005","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104222","article-title":"Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression","volume":"358","author":"De Paula Pohl","year":"2020","journal-title":"Cell Immunol"},{"key":"B55","unstructured":"A study of anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy in subjects with non-relapsing and progressive forms of multiple sclerosis\n          \n          \n          \n          2024"},{"key":"B56","unstructured":"A study of KYV-101, a CD19 CAR T cell therapy, in participants with treatment refractory progressive multiple sclerosis\n          \n          \n          \n          2024"},{"key":"B57","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26020467","article-title":"Exploring CAR T-cell dynamics: balancing potent cytotoxicity and controlled inflammation in CAR T-cells derived from systemic sclerosis and myositis patients","volume":"26","author":"Dingfelder","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B59","unstructured":"KYSA-7: A study of anti-CD19 CAR T-cell therapy, in subjects with refractory primary and secondary progressive multiple sclerosis\n          \n          \n          \n          2024"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e179742","DOI":"10.1172\/JCI179742","article-title":"Myasthenia gravis: the future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"J Clin Invest"},{"key":"B61","unstructured":"Autologous T-cells expressing A chimeric antigen receptor directed to B-cell maturation antigen (BCMA) in patients with generalized myasthenia gravis (MG)\n          \n          \n          \n          2019"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"B64","unstructured":"KYSA-6: A phase 2, open-label, multicentre study of KYV-101, an autologous fully human anti-CD19 chimeric antigen receptor T-cell (CD19 CAR T) therapy, in subjects with refractory generalized myasthenia gravis\n          \n          \n          \n          2024"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B66","unstructured":"A phase 1, open-label, safety and dose-finding study of autologous muscle-specific tyrosine kinase chimeric autoantibody receptor T cells (MuSK-CAART) in subjects with anti-MuSK-antibody-positive myasthenia gravis\n          \n          \n          \n          2022"},{"key":"B67","unstructured":"A phase 1, multicenter, single-arm, dose-escalation study of CC-97540 (BMS-986353), CD19-targeted NEX-T chimeric antigen receptor (CAR) T cells, evaluating safety and tolerability in participants with autoimmune neurological diseases: relapsing forms of multiple sclerosis (RMS), progressive forms of multiple sclerosis (PMS), or refractory myasthenia gravis (MG)\n          \n          \n          \n          2022"},{"key":"B68","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J Neuroinflammation"},{"key":"B69","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B70","unstructured":"A study on the safety and efficacy of chimeric antigen receptor T cells in the treatment of recurrent\/refractory neuromyelitis optica\n          \n          \n          \n          2023"},{"key":"B71","unstructured":"An exploratory clinical study of cluster of differentiation antigen 20(CD20)\/anti-B-cell maturation antigen (BCMA) chimeric antigen receptor autologous T cell product (C-CAR168) in the treatment of autoimmune diseases refractory to standard therapy\n          \n          \n          \n          2024"},{"key":"B72","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s001090050092","article-title":"Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis","volume":"75","author":"Bernard","year":"1997","journal-title":"J Mol Med (Berl)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010100","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: limit Insights into the Disease Pathophysiology, Diagnosis and Management","volume":"22","author":"Ambrosius","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200292","article-title":"CD19-directed CAR T-cells in a patient with refractory MOGAD: clinical and immunologic follow-up for 1 year","volume":"11","author":"Cabrera-Maqueda","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B75","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/jalm\/jfab102","article-title":"Autoimmune encephalitis and autoantibodies: A review of clinical implications","volume":"7","author":"H\u00e9bert","year":"2022","journal-title":"J Appl Lab Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J Neurosci"},{"key":"B77","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"B78","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41582-024-01012-3","article-title":"Stiff-person syndrome and related disorders - diagnosis, mechanisms and therapies","volume":"20","author":"Dalakas","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2403227121","article-title":"Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome","volume":"121","author":"Faissner","year":"2024","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B80","unstructured":"KYSA-8: A phase 2 open-label, single-arm, multicenter study of KYV 101, an autologous fully human anti-CD19 chimeric antigen receptor T cell (CD19 CAR T) therapy, in subjects with treatment refractory stiff person syndrome\n          \n          \n          \n          2024"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-320314","article-title":"Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment","volume":"90","author":"Lehmann","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlife.2024.05.005","article-title":"BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy","volume":"2","author":"Zhang","year":"2024","journal-title":"hLife"},{"key":"B83","unstructured":"An exploratory study on the safety and efficacy of universal CAR-T cells targeting BCMA and CD19 in the treatment of refractory autoimmune diseases of the nervous system\n          \n          \n          \n          2020"},{"key":"B84","unstructured":"An open label clinical trial to evaluate the safety and efficacy of CT103A cells for the treatment of relapsed\/refractory antibody-associated inflammatory diseases of the nervous system\n          \n          \n          \n          2020"},{"key":"B85","unstructured":"A phase 1, open-label study to evaluate the safety and clinical activity of azercabtagene zapreleucel in participants with B-cell mediated autoimmune disorders\n          \n          \n          \n          2025"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2019.10.4.11","article-title":"CAR T-cell therapy: adverse events and management","volume":"10","author":"Adkins","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30277-5","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis","volume":"7","author":"Anagnostou","year":"2020","journal-title":"Lancet Haematol"},{"key":"B89","article-title":"Current strategies for the treatment of autoimmune diseases","volume":"24","author":"Rosato","year":"2010","journal-title":"J Biol Regul Homeost Agents"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.2174\/157015911796557939","article-title":"Toxicities of immunosuppressive treatment of autoimmune neurologic diseases","volume":"9","author":"Lallana","year":"2011","journal-title":"Curr Neuropharmacol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"J Neurol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1476859","article-title":"CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33156","article-title":"Cost of decentralized CAR T-cell production in an academic nonprofit setting","volume":"147","author":"Ran","year":"2020","journal-title":"Int J Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102778","article-title":"Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals","volume":"50","author":"Boyko","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B97","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101555","article-title":"The thin red line between the immune system and cancer evolution","volume":"27","author":"Baxevanis","year":"2023","journal-title":"Transl Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1432985","article-title":"Autoimmunity: the neoantigen hypothesis","volume":"15","author":"Mustelin","year":"2024","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri724","article-title":"Epitope spreading in immune-mediated diseases: implications for immunotherapy","volume":"2","author":"Vanderlugt","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e19763","article-title":"Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: An in-vitro study","volume":"9","author":"Sahlolbei","year":"2023","journal-title":"Heliyon"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.979116","article-title":"Tumor accomplice: T cell exhaustion induced by chronic inflammation","volume":"13","author":"Fang","year":"2022","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2016.04.011","article-title":"Refractory autoimmune disease: an overview of when first-line therapy is not enough","volume":"53","author":"Neunert","year":"2016","journal-title":"Semin Hematol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447337","article-title":"Autoimmune diseases refractory to corticosteroids and immunosuppressants","volume":"15","author":"Elkoshi","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1604174\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T05:24:12Z","timestamp":1752816252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1604174\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":106,"alternative-id":["10.3389\/fimmu.2025.1604174"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1604174","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"article-number":"1604174"}}